MX2018010367A - Titulacion de cebranopadol. - Google Patents

Titulacion de cebranopadol.

Info

Publication number
MX2018010367A
MX2018010367A MX2018010367A MX2018010367A MX2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A
Authority
MX
Mexico
Prior art keywords
cebranopadol
daily dose
administration interval
administered
administration
Prior art date
Application number
MX2018010367A
Other languages
English (en)
Spanish (es)
Inventor
Wang Shaonan
Piana Chiara
Bursi Roberta
Original Assignee
Guenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guenenthal Gmbh filed Critical Guenenthal Gmbh
Publication of MX2018010367A publication Critical patent/MX2018010367A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018010367A 2016-02-29 2017-02-28 Titulacion de cebranopadol. MX2018010367A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16157868 2016-02-29
EP16020302 2016-08-11
PCT/EP2017/025034 WO2017148595A1 (en) 2016-02-29 2017-02-28 Titration of cebranopadol

Publications (1)

Publication Number Publication Date
MX2018010367A true MX2018010367A (es) 2018-12-10

Family

ID=58185482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010367A MX2018010367A (es) 2016-02-29 2017-02-28 Titulacion de cebranopadol.

Country Status (10)

Country Link
US (3) US11229625B2 (https=)
EP (1) EP3423054A1 (https=)
JP (2) JP7373904B2 (https=)
CN (2) CN109069483A (https=)
AU (1) AU2017226830B2 (https=)
BR (1) BR112018017167A2 (https=)
CA (1) CA3015420C (https=)
IL (1) IL261133A (https=)
MX (1) MX2018010367A (https=)
WO (1) WO2017148595A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL348808A1 (en) * 1998-11-02 2002-06-17 Ortho Mcneil Pharm Inc Analgesic regimen
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DK1572167T3 (da) 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
WO2012016699A2 (en) 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
KR20130097173A (ko) * 2010-08-04 2013-09-02 그뤼넨탈 게엠베하 신경병증성 통증을 치료하기 위한 ６’­플루오로­（Ｎ­메틸­ 또는 Ｎ，Ｎ­디메틸­）­４­페닐­４’，９’­디하이드로­３’Ｈ­스피로[사이클로헥산­１，１’­피라노[３，４，ｂ]인돌]­４­아민을 포함하는 약제학적 투여형
WO2012016703A2 (en) 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
AU2011287952B2 (en) 2010-08-04 2014-08-21 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane- 1,1'-pyrano[3,4,b]indol]-4-amine
EP2649044B1 (en) 2010-12-08 2017-09-20 Grünenthal GmbH Method for synthesising substituted aminocyclohexanone derivatives
US8614245B2 (en) 2011-07-08 2013-12-24 Gruenenthal Gmbh Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
CN103649094B (zh) 2011-07-08 2017-05-24 格吕伦塔尔有限公司 晶态的(1r,4r)‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺
ES2605786T3 (es) 2011-12-12 2017-03-16 Grünenthal GmbH Formas sólidas de clorhidrato de (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4b]indol]-4-amina
RS54960B1 (sr) 2011-12-12 2016-11-30 Gruenenthal Gmbh Čvrsti oblici (1r,4r)-6'-fluoro-(n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-spiro-[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amina i sumporne kiseline
CN104159902B (zh) 2011-12-12 2016-05-04 格吕伦塔尔有限公司 制备(1r,4r)-6’-氟-(N,N-二甲基-和N-甲基)-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的方法
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9308196B2 (en) 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
EP3110797B1 (en) 2014-02-27 2018-08-29 Grünenthal GmbH Process for the preparation of 5-fluorotryptophol
JP6673924B2 (ja) 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定

Also Published As

Publication number Publication date
CN109069483A (zh) 2018-12-21
JP2019507148A (ja) 2019-03-14
JP2021169472A (ja) 2021-10-28
IL261133A (en) 2018-10-31
CN118286209A (zh) 2024-07-05
EP3423054A1 (en) 2019-01-09
US20180369199A1 (en) 2018-12-27
CA3015420A1 (en) 2017-09-08
CA3015420C (en) 2023-09-26
US20250255849A1 (en) 2025-08-14
US11229625B2 (en) 2022-01-25
BR112018017167A2 (pt) 2019-01-02
AU2017226830A1 (en) 2018-08-16
JP7373904B2 (ja) 2023-11-06
US12161627B2 (en) 2024-12-10
US20220110914A1 (en) 2022-04-14
AU2017226830B2 (en) 2021-06-24
WO2017148595A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX2020004084A (es) Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion.
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
PE20151438A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
CL2021001389A1 (es) Formulaciones en cápsula
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CL2022001692A1 (es) Compuestos activos frente a receptores nucleares
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
CL2025000581A1 (es) Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren